Co-author: Jessica Burris
Co-authored publications (5):
- Long MD , Parlett LE , Lewis JD et al . Corticosteroids but not anti-TNF are associated with increased COVID-19 complications in patients with inflammatory bowel disease .Inflamm Bowel Dis. 2024; 30 (8) : 1345–52 . doi: 10.1093/ibd/izad176 .
- Adimadhyam S , Lewis JD , Simon AL et al . Real-world evidence comparing tofacitinib and vedolizumab in anti-TNF-experienced patients with ulcerative colitis .Inflamm Bowel Dis. 2024; 30 (4) : 554-62 . doi: 10.1093/ibd/izad115 .
- Kappelman MD , Lewis JD , Zhang X et al . Comparing patient-reported outcomes among anti-TNF-experienced patients with crohn's disease initiating vedolizumab versus ustekinumab .Dig Dis Sci. 2023; 68 (8) : 3413-20 . doi: 10.1007/s10620-023-07942-0 .
- Kappelman MD , Long MD , Zhang X et al . Comparing patient-reported outcomes among anti-TNF experienced patients with ulcerative colitis initiating vedolizumab versus tofacitinib .Crohns Colitis 360. 2023; 5 (3) : otad031 . doi: 10.1093/crocol/otad031 .
- Kappelman MD , Adimadhyam S , Hou L et al . Real-world evidence comparing vedolizumab and ustekinumab in antitumor necrosis factor-experienced patients with crohn's disease .Am J Gastroenterol. 2023; 118 (4) : 674-84 . doi: 10.14309/ajg.0000000000002068 .